Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
IKT Stock Chart & Stats
$1.56
$0.06(1.71%)
At close: 4:00 PM EST
$1.56
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $3.32
Previous CloseN/A
Volume38.02K
Average Volume (3M)132.72K
Market Cap
$189.18M
Enterprise Value$73.91M
Total Cash (Recent Filing)$77.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Mar 26, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding121,267,044
10 Day Avg. Volume124,469
30 Day Avg. Volume132,718
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.38
Price to Sales (P/S)0.00
P/FCF Ratio-11.77
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.10K
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$6.20Price Target Upside297.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignAnalyst notes that an FDA-agreed two-part adaptive Phase 3 trial with a dose-titration stage can shorten development timelines and improve the chance of demonstrating IKT-001's benefit.
Early Clinical Signals And Clinician InterestAnalyst cites encouraging early clinical data for IKT-001 and strong clinician interest in tyrosine kinase inhibitors as evidence the program may gain clinical adoption.
Regulatory Pathway And Manufacturing ReadinessAnalyst points to recognition of IKT-001 as a new molecular entity and progression via a 505(b)(2) pathway, while enhanced manufacturing process development supports late-stage readiness.
Bears Say
Delivery Method OverhangAnalyst warns that the failure of a dry powder inhalation approach creates an overhang for the program and may sustain investor skepticism despite differences in delivery methods.
Serious Safety EventsAnalyst highlights prior imatinib safety concerns, including subdural hematoma events in patients on anticoagulants, which could complicate regulatory review and labeling.
Tolerability And Market Adoption RiskAnalyst notes historical poor tolerability of imatinib led to high discontinuation rates, which could limit patient uptake unless tolerability is clearly improved.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $3.32 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $189.18M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 48 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, the consensus estimate of -$0.13 by $0.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 121,267,044 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.13 in its last earnings report, expectations of -$0.13. Following the earnings report the stock price went down -0.654%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.20 (297.44% Upside)
$6.20 (297.44% Upside)
Hedge Fund Trend
Decreased
By 10.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.19%
12-Months-Change
Fundamentals
Return on Equity
-131.71%
Trailing 12-Months
Asset Growth
906.63%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
IKT Stock 12 Month Forecast
Average Price Target
$6.20
▲(297.44% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―